Alkem Laboratories Ltd. · NSE:ALKEM
Alkem Laboratories — Q1 FY2017 Earnings Presentation
12 slides from Alkem Laboratories's earnings presentation, Aug 12, 2016
Slide 1: Alkem Laboratories Limited Investor Presentation Q1FY17
Alkem Laboratories Limited Investor Presentation Q1FY17 12th August 2016
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and
Slide 3: Key Financial Highlights – Q1FY17 Consolidated
Key Financial Highlights – Q1FY17 Consolidated All figures in INR mn Net Revenue from Operations India sales 10,803 8,827 14,579 12,075 Q1FY16 Q1FY17 International sales 3,590 3,134 Q1FY16 Q1FY17 Q1FY16 Q1FY17
Slide 4: Key Financial Highlights – Q1FY17 Consolidated
Key Financial Highlights – Q1FY17 Consolidated All figures in INR mn Gross Profit and Gross Margin EBITDA and EBITDA Margin 2,711 8,790 7,331 2,062 60.7% 60.3% 17.1% 18.6% Q1FY16 Q1FY17 Q1FY16 Q1FY17 PBT (before Minority Interest) PAT (after Minority Interest) 2,388 2,663 2,011 2,107 Q1FY16 Q1FY17 Q
Slide 5: India Business
India Business India Business: Q1FY17 Net Sales of Rs.10,803 million (22.4% growth YoY) • India sales contributed 75.1% to total net sales for Q1FY17 India sales INR mn • The robust growth during the quarter was delivered amidst the challenging environment with expansion of NLEM list, WPI led 10.803
Slide 6: India Business – Therapy performance in Q1FY17
Established therapeutic India Business – Therapy performance in Q1FY17 Market rank 1 3 3 5 areas of Alkem Market share3 12.5% 5.9% 5.1% 3.8% 14.6% 9.4% 10.4% 9.0% 7.0% 8.0% 5.8% 3.3% Anti-infectives Gastro-intestinal Pain/ Analgesics Vitamins/ Minerals / Nutrients Alkem sales growth YoY2,3 Indian ph
Slide 7: US Business
US Business US Business: Q1FY17 Net Sales of Rs.2,719 million (11.8% growth YoY) • US sales contributed 18.9% to total net sales for Q1FY17 • The Company launched 3 new products towards later half of Q1FY17, of which one was in-licensed product • During the quarter, the Company received 3 tentative
Slide 8: Other International Markets
Other International Markets Other International Markets : Q1FY17 Net Sales of Rs.871 million (24.0% growth YoY) Other International Markets sales • Other International sales contributed 6.0% to total net sales for INR mn Q1FY17 • Company has presence in more than 50 international markets 871 • The g
Slide 9: Strategy going forward
Strategy going forward 1 India Sales: Consolidate our leadership position in the acute segment by driving growth in our mega brands 2 India Sales: Increase our market share in the chronic segment through market share acquisition and new product introductions 3 Improve our field force productivity th
Slide 10: Financials – Key P&L items (Consolidated)
Financials – Key P&L items (Consolidated) Particulars (Rs mn) Q1FY17 Q1FY16 YoY growth Net Income from Operations 14,579 12,075 20.7% Gross Profit 8,790 7,331 19.9% Gross Profit margin 60.3% 60.7% EBITDA 2,711 2,062 31.5% EBITDA margin 18.6% 17.1% PBT 2,663 2,107 26.4% PBT margin 18.3% 17.4% PAT (Af
Slide 11: Latest Shareholding Pattern
Latest Shareholding Pattern Shareholding pattern as on 30th June 2016 Non-Institution, 26.21% Promoter & Institution, Promoter Group, 6.91% 66.88% Institution – Mutual Funds, Financial Institutions, Foreign Portfolio Investors, Foreign Institutional Investors, Nationalised and Non-Nationalised Banks
Slide 12: Thank You
———— J < —% Thank You ’ .